MIRA Pharmaceuticals, Inc.
News
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Accesswire MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and...\n more…
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
Accesswire Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA...\n more…
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Benzinga Shares of MIRA Pharmaceuticals, Inc. MIRA rose sharply in today's pre-market trading after company announced it achieved 100% reversal of neuropathic pain with oral Ketamin-2 in a rat study. MIRA Pharmaceuticals shares jumped 44.8% to $2.68 in the pre-market trading. Here are some other stocks moving in pre-market trading.\n more…
Q3 2024 Earnings Forecast for MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Issued By Zacks Small Cap
Ticker Report MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Free Report) - Equities research analysts at Zacks Small Cap lifted their Q3 2024 earnings estimates for shares of MIRA Pharmaceuticals in a report released...\n more…
